Tumor Hypoxia: Impact on Radiation Therapy and Molecular Pathways
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Tumor hypoxia is a common feature of the microenvironment in solid tumors, primarily due to an inadequate, and heterogeneous vascular network. It is associated with resistance to radiotherapy and results in a poorer clinical outcome. The presence of hypoxia in tumors can be identified by various invasive and non-invasive techniques, and there are a number of approaches by which hypoxia can be modified to improve outcome. However, despite these factors and the ongoing extensive pre-clinical studies, the clinical focus on hypoxia is still to a large extent lacking. Hypoxia is a major cellular stress factor and affects a wide range of molecular pathways, and further understanding of the molecular processes involved may lead to greater clinical applicability of hypoxic modifiers. This review is a discussion of the characteristics of tumor hypoxia, hypoxia-related molecular pathways, and the role of hypoxia in treatment resistance. Understanding the molecular aspects of hypoxia will improve our ability to clinically monitor hypoxia and to predict and modify the therapeutic response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735
Hypoxia-inducible factors in physiology and medicine
Semenza, G. L. (2012) · Cell · doi:10.1016/j.cell.2012.01.021 · Cited by 3,645
Tumorigenesis and the angiogenic switch
Bergers, G., & Benjamin, L. E. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1093 · Cited by 3,559 · cited 1×
“To compensate, tumors develop their own functional vascular supply from the normal host vascular network by the process of angiogenesis (3, 4).”
BackgroundOtto Warburg's contributions to current concepts of cancer metabolism
Koppenol, W. H., Bounds, P. L., & Dang, C. V. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3038 · Cited by 3,427
Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
Tumor Hypoxia: Definitions and Current Clinical, Biologic, and Molecular Aspects
Hockel, M., & Vaupel, P. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.4.266 · Cited by 2,662
A conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184
Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166 · cited 1×
“A rapid and selective upregulation of PD-L1 is induced by hypoxia on MDSCs, and significant increased expression of PD-L1 on macrophages, dendritic cells and tumor cells, all due to HIF1 binding directly to the HRE in the PD-L1 proximal promoter (68).”
BackgroundGray, L. H., Conger, A. D., Ebert, M., Hornsey, S., & Scott, O. C. A. (1953) · The British Journal of Radiology · doi:10.1259/0007-1285-26-312-638 · Cited by 2,158
Transcriptional control of human p53-regulated genes
Riley, T., Sontag, E., Chen, P., & Levine, A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2395 · Cited by 1,921 · cited 1×
“Activation of p53 is a consequence of the hypoxia induced DDR, by phosphorylation at a number of residues (45, 46).”
BackgroundHIF-1: mediator of physiological and pathophysiological responses to hypoxia
Semenza, G. L. (2000) · Journal of Applied Physiology · doi:10.1152/jappl.2000.88.4.1474 · Cited by 1,822 · cited 1×
“The hypoxia-mediated intracellular signaling pathways are predominantly orchestrated by intracellular signaling, mainly under control by a family of transcription factors, the hypoxia inducible factors (HIFs) (12, 13).”
BackgroundGeneral involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia.
Wang, G. L., & Semenza, G. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.9.4304 · Cited by 1,468 · cited 1×
“HIF upregulates target gene expression through binding at the hypoxia responsive elements (HREs) in the enhancer and promotor regions of the target genes (14).”
BackgroundRankin, E. B., & Giaccia, A. J. (2016) · Science · doi:10.1126/science.aaf4405 · Cited by 1,340 · cited 1×
“It promotes an immunosuppressive microenvironment by regulating the recruitment of T-cells, myeloid-derived suppressor cells (MDSCs), macrophages, and neutrophils (64, 65).”
BackgroundCellular Adaptation to Hypoxia through Hypoxia Inducible Factors and beyond
Lee, P., Chandel, N. S., & Simon, M. C. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0227-y · Cited by 1,272 · cited 2×
“ER stress is the result of an accumulation of unfolded or misfolded proteins, as oxygen depletion can interfere with protein folding (29, 30) Unlike HIF, which is activated at oxygen concentrations below 2%, UPR is activated at exposure to more severe hypoxia (<0.”
BackgroundJiang, B. H., Semenza, G. L., Bauer, C., & Marti, H. H. (1996) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1996.271.4.c1172 · Cited by 1,213 · cited 1×
“At oxygen concentrations around 2% O2 and below this hydroxylation is suppressed leading HIFα to not be degraded (20, 21), and form the active transcription complex with HIF-1β, which induce transcriptional upregulation of a broad range of target genes (22–24).”
BackgroundKinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation
Winkler, F., Kozin, S. V., Tong, R. T., Chae, S.-S., Booth, M. F., Garkavtsev, I., Xu, L., Hicklin, D. J., Fukumura, D., di Tomaso, E., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.011 · Cited by 1,170
Hypoxia, DNA repair and genetic instability
Bristow, R. G., & Hill, R. P. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2344 · Cited by 1,140
Cytoplasmic functions of the tumour suppressor p53
Green, D. R., & Kroemer, G. (2009) · Nature · doi:10.1038/nature07986 · Cited by 1,106 · cited 1×
“Activation of p53 is a consequence of the hypoxia induced DDR, by phosphorylation at a number of residues (45, 46).”
BackgroundMolecular landmarks of tumor hypoxia across cancer types
Bhandari, V., Hoey, C., Liu, L. Y., Lalonde, E., Ray, J., Livingstone, J., Lesurf, R., Shiah, Y.-J., Vujcic, T., Huang, X., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0318-2 · Cited by 678
Imaging hypoxia to improve radiotherapy outcome
Horsman, M. R., Mortensen, L. S., Petersen, J. B., Busk, M., & Overgaard, J. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.171 · Cited by 614 · cited 4×
“Regardless of whether one type of hypoxia is more of a negative factor, there is good clinical evidence that hypoxia significantly impacts patient outcome following radiation therapy (71).”
BackgroundMethodInfluentialSelf-citationImmunological mechanisms of the antitumor effects of supplemental oxygenation
Hatfield, S. M., Kjaergaard, J., Lukashev, D., Schreiber, T. H., Belikoff, B., Abbott, R., Sethumadhavan, S., Philbrook, P., Ko, K., Cannici, R., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa1260 · Cited by 600 · cited 2×
“Interestingly, one pre-clinical study using a variety of tumor models showed that by allowing tumor-bearing mice to breathe high oxygen content gas (60% oxygen) rather than the normal 21% oxygen, resulted in an inhibition of tumor progression, a decrease in metastatic disease, and prolonged animal survival (67).”
BackgroundRelation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers
Winter, S. C., Buffa, F. M., Silva, P., Miller, C., Valentine, H. R., Turley, H., Shah, K. A., Cox, G. J., Corbridge, R. J., Homer, J. J., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3322 · Cited by 410
Eustace, A., Mani, N., Span, P. N., Irlam, J. J., Taylor, J., Betts, G. N. J., Denley, H., Miller, C. J., Homer, J. J., Rojas, A. M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0542 · Cited by 240 · cited 1×
“(121), is another hypoxia signature in HNSCC.”
“Translating” Tumor Hypoxia: Unfolded Protein Response (UPR)–Dependent and UPR-Independent Pathways
Koumenis, C., & Wouters, B. G. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0150 · Cited by 228
Bracken, C. P., Fedele, A. O., Linke, S., Balrak, W., Lisy, K., Whitelaw, M. L., & Peet, D. J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600288200 · Cited by 222
Hypoxia-inducible factors: a central link between inflammation and cancer
Triner, D., & Shah, Y. M. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84430 · Cited by 199
Inherent DNA‐binding specificities of the HIF‐1α and HIF‐2α transcription factors in chromatin
Smythies, J. A., Sun, M., Masson, N., Salama, R., Simpson, P. D., Murray, E., Neumann, V., Cockman, M. E., Choudhry, H., Ratcliffe, P. J., et al. (2019) · The EMBO Reports · doi:10.15252/embr.201846401 · Cited by 195
Kietzmann, T., Mennerich, D., & Dimova, E. Y. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00011 · Cited by 176
Modulation of the tumor vasculature and oxygenation to improve therapy
Siemann, D. W., & Horsman, M. R. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.06.006 · Cited by 169 · cited 7×
“Micro-regional areas are thus formed within the tumor that are characterized by glucose and energy deprivation, high lactate levels and extracellular acidity, and oxygen deficiency (1, 2).”
BackgroundInfluentialSelf-citationHIF-1 versus HIF-2 — Is one more important than the other?
Loboda, A., Jozkowicz, A., & Dulak, J. (2012) · Vascular Pharmacology · doi:10.1016/j.vph.2012.02.006 · Cited by 152 · cited 1×
“HIF1 and HIF2 have structural similarities and identical DNA recognition motifs, but binds to different cell-specific sites across the genome (26, 27).”
BackgroundThe tumour hypoxia induced non-coding transcriptome
Choudhry, H., Harris, A. L., & McIntyre, A. (2016) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2016.01.003 · Cited by 120
Vaupel, P., & Multhoff, G. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01887 · Cited by 81 · cited 2×
“Hypoxia seems to play a significant role in influencing anti-cancer immune responses (62, 63).”
Background
Cited by
Choi, Y., & Jung, K. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01114-w · Cited by 188
Davis, L., Recktenwald, M., Hutt, E., Fuller, S., Briggs, M., Goel, A., & Daringer, N. (2022) · Cancers · doi:10.3390/cancers14051259 · Cited by 83
Effects of hypoxia and nanocarrier size on pH-responsive nano-delivery system to solid tumors
Soltani, M., Souri, M., & Moradi Kashkooli, F. (2021) · Scientific Reports · doi:10.1038/s41598-021-98638-w · Cited by 82
Metadata
- Authors
- Sørensen, B. S., & Horsman, M. R.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2020-04-21
- Volume
- 10
- Pages
- 562-562
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W3019242196
- Cited by
- 229
- References
- 36
- FWCI
- 9.35
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.